Company: APM
Filing Date: 2025-01-03
Form Type: 424B5
Source: 0001213900-25-000606
Chunk: 29

Company: Aptorum Group Ltd
Filing Date: 2025-01-03
Form: 424B5
Chunk 29
---
| ● | “Registered Direct Offering” means the registered direct offering by the Company of 1,351,350 Class A Ordinary Shares and warrants to purchase up to 1,351,350 Class A Ordinary Share consummated on February 28, 2020. |
| ● | “Resale Shares” refers to the Class A Ordinary Shares underlying the Selling Shareholder Warrants, as such term is herein after defined.                                                                                |

<div align='center'>v</div>

| ● 
 ● | “Restructure” refers to the Company’s change from an investment fund with management shares and non-voting participating redeemable preference shares to a holding company with operating subsidiaries, effective as of March 1, 2017.                                                                                                                                                                                                                                                                                                                                                                                             
 “Registration Statement” refers to the Company’s Registration Statement on Form F-1 (File No. 333-227198) for the sale of up to 3,493,969 Class A Ordinary Shares (including Class A Ordinary Shares underlying certain warrants and a bond, as fully described therein) which initially filed on September 5, 2018 and became effective on December 3, 2018.                                                                                                                                                                                                                                                                      |
|:--|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ● | “R&D” refers to research and development.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| ● | “R&D Center” refers to an in-house pharmaceutical development center located in Hong Kong Science and Technology Park.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| ● | “Securities Exchange Commission,” “SEC,” “Commission” or similar terms refer to the Securities Exchange Commission.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| ● | “Sarbanes-Oxley Act” refers to the Sarbanes-Oxley Act of 2002.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| ● | “Scipio” refers to Scipio Life Sciences Limited, a variable interest entity in which we hold 97.93% economic interest and 35.06% voting power. We are the primary beneficiary of Scipio.                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| ● | “Securities Act” refers to the Securities Act of 1933.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| ● | “Selling Shareholder Warrants” refer to the 540,540 remaining warrants to purchase shares of Class A Ordinary Shares at an adjusted exercise price of $0 per share, issued to the selling shareholder noted herein, pursuant to the offering we conducted in February 2020 pursuant to